Right to Try Act

Published by IRDiRC

Early Access Support Life-Threatening Disease Orphan Medicine Regulatory Regulatory Affairs Right to Try Act

This law is another way for patients who have been diagnosed with life-threatening diseases or conditions who have tried all approved treatment options and who are unable to participate in a clinical trial to access certain unapproved treatments.

View this resource Bookmark this resource

Single Patient Expanded Access

Published by IRDiRC

Early Access Support Orphan Drug Orphan Medicine Regulatory Affairs Research and Drug Development Single Patient Expanded Accesss

This FDA program allows early access to drugs and medical devices before marketing approval, under regulatory oversight with collection of Safety data, to individual patients with serious or immediately life-threatening diseases or conditions who lack therapeutic alternatives. This includes emergency and non-emergency expanded access.

View this resource Bookmark this resource

US Expanded Access Program

Published by IRDiRC

Early Access Support Expanded Accesss Programme Orphan Drug Orphan Medicine Regulatory Affairs Research and Drug Development

The Program allows patients with serious rare diseases to have access to pre-market drugs and devices, if the Sponsor agrees to this under their expanded access policy

View this resource Bookmark this resource

INTERACT Meetings (Initial Targeted Engagement for Regulatory Advice on CBER products)

Published by IRDiRC

Drug Development Advice Early Access Support Regulatory Advice Regulatory Affairs Scientific Advice Targeted Engagement for Regulatory Advice

Through a CBER Initial Targeted Engagement for Regulatory Advice on CBER producTs (INTERACT) meeting, sponsors can obtain initial, nonbinding advice from FDA regarding chemistry, manufacturing and controls, pharmacology/Toxicology, and/or clinical aspects of the development program

View this resource Bookmark this resource

Patient-focused drug development program

Published by IRDiRC

Early Access Support Patient Advice Patient Focused Drug Development Programme Patient Support Regulatory Advice Regulatory Affairs

The Patient-focused Drug Development (PFDD) program was initiated at FDA from 2012- 2017 under Congressional Mandate (PDUFA V) to more systematically obtain the patient perspective on specific diseases and their treatments. PFDD meetings provide key stakeholders an opportunity to hear the patient’s voice.

View this resource Bookmark this resource

Stakeholders interactions – Professional affairs and Community Engagement

Published by IRDiRC

Clinical Trial Community Engagement Early Access Support Early Stage Interaction Patient Advice Professional Affairs Regulatory Advice Regulatory Affairs Scientific Advice

Interaction of the stakeholders and multilateral education at an early stage of development will facilitate drug development (e.g. ensuring outcome measures for clinical trials are developed that are meaningful for patients, are acceptable to the regulators, and are acceptable to payers)

View this resource Bookmark this resource

FDA Pediatrics Advisory Committee

Published by IRDiRC

Biomedical Ethics Early Access Support Paediatric Medicine Paediatric Regulation Paediatric Research Paedriatic Advisory Committee Regulatory Advice Regulatory Affairs

The Pediatric Advisory Committee (PAC) is a committee of authorities knowledgeable in pediatric research, pediatric subspecialties, statistics, and/or biomedical ethics who advise and make recommendations to the FDA

View this resource Bookmark this resource

FDA Expedited Program for serious conditions – Fast Track Designation

Published by IRDiRC

Early Access Support Expedited Programme Fast Track Designation Rare Disease Regulatory Advice Regulatory Affairs

Process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.

View this resource Bookmark this resource

US Orphan Drug Designation

Published by IRDiRC

Early Access Support Orphan Drug Designation Orphan Drug Incentive Regulatory Advice Regulatory Affairs

The ODA is intended to provide incentives for Orphan Drug development and to defray the costs of qualified clinical testing expenses incurred in connection with the development of drugs for rare diseases and conditions.

View this resource Bookmark this resource

Product specific- pre approval advisory committee

Published by IRDiRC

Advisory Commitee Approval Advisory Committee Early Access Support Regulatory Affairs Scientific Advice Technical Advice

Advisory committees (AC) provide independent advice and recommendations the US FDA on scientific and technical matters related to the development and evaluation of products regulated by the FDA

View this resource Bookmark this resource

The Innovation Management Toolbox was originally developed through funding from the EJP RD project, which received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 825575. The continued development and maintenance of the Toolbox are now supported by the ERDERA partnership, funded under the European Union’s Horizon Europe Research & Innovation programme, grant agreement No. 101156595.

IMT Feedback

Did the IMT help you in finding the resource you needed?

Right to Try Act

Single Patient Expanded Access

US Expanded Access Program

INTERACT Meetings (Initial Targeted Engagement for Regulatory Advice on CBER products)

Patient-focused drug development program

Stakeholders interactions – Professional affairs and Community Engagement

FDA Pediatrics Advisory Committee

FDA Expedited Program for serious conditions – Fast Track Designation

US Orphan Drug Designation

Product specific- pre approval advisory committee